228 related articles for article (PubMed ID: 28849698)
1. Imaging Neurotensin Receptor in Prostate Cancer With
Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z
Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698
[TBL] [Abstract][Full Text] [Related]
2. Preclinical PET Imaging of NTSR-1-Positive Tumors with
Li D; Minnix M; Allen R; Bading J; Chea J; Wong P; Bowles N; Poku E; Shively JE
Cancer Biother Radiopharm; 2021 Oct; 36(8):651-661. PubMed ID: 32822229
[No Abstract] [Full Text] [Related]
3. Development of [
Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
[TBL] [Abstract][Full Text] [Related]
4. Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor.
Wu Z; Li L; Liu S; Yakushijin F; Yakushijin K; Horne D; Conti PS; Li Z; Kandeel F; Shively JE
J Nucl Med; 2014 Jul; 55(7):1178-84. PubMed ID: 24854793
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.
Deng H; Wang H; Wang M; Li Z; Wu Z
Mol Pharm; 2015 Aug; 12(8):3054-61. PubMed ID: 26162008
[TBL] [Abstract][Full Text] [Related]
6. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
7.
Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
[TBL] [Abstract][Full Text] [Related]
8. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
9. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.
He T; Wang M; Wang H; Tan H; Tang Y; Smith E; Wu Z; Liao W; Hu S; Li Z
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2199-2207. PubMed ID: 31264168
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
12. Evidence of
Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M
Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211
[TBL] [Abstract][Full Text] [Related]
13. Syntheses, receptor bindings, in vitro and in vivo stabilities and biodistributions of DOTA-neurotensin(8-13) derivatives containing β-amino acid residues - a lesson about the importance of animal experiments.
Sparr C; Purkayastha N; Yoshinari T; Seebach D; Maschauer S; Prante O; Hübner H; Gmeiner P; Kolesinska B; Cescato R; Waser B; Reubi JC
Chem Biodivers; 2013 Dec; 10(12):2101-21. PubMed ID: 24327436
[TBL] [Abstract][Full Text] [Related]
14. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
15. Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14).
Fournier P; Dumulon-Perreault V; Ait-Mohand S; Tremblay S; Bénard F; Lecomte R; Guérin B
Bioconjug Chem; 2012 Aug; 23(8):1687-93. PubMed ID: 22770480
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
19. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
Yang YS; Zhang X; Xiong Z; Chen X
Nucl Med Biol; 2006 Apr; 33(3):371-80. PubMed ID: 16631086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]